Chongqing, China – As the wheel of time turned to mark two extraordinary decades, Porton Pharma Solutions, one of the global leaders in Contract Development and Manufacturing Organization (CDMO) services, recently celebrated its 20th anniversary with a grand celebration in Chongqing, China. Global partners and industry leaders gathered to honor this pivotal milestone, celebrating Porton’s journey from its humble beginnings to a trusted enabler of global healthcare innovation.

Founded in 2005 by three visionary entrepreneurs with the mission of “Enabling the Public’s Early Access to Good Medicines,” Porton began its journey. A year later, it launched its Chongqing and Chengdu manufacturing site and R&D center respectively, laying the foundation for its future as a trusted global CMO.



In 2014, Porton achieved a pivotal milestone with its listing on the Shenzhen Stock Exchange’s ChiNext Board (SZSE: 300363), unlocking new growth opportunities and accelerating its global footprint. Since then, the company has strategically expanded from its origins—opening and expanding several GMP manufacturing facilities and process R&D centers—to establish a truly international presence.



Today, Porton Pharma Solutions has passed FDA, EMA, WHO, PMDA and NMPA inspections, a testament to its stringent quality standards and regulatory compliance. Our network spans 18 locations worldwide, with a total capacity of around 2200m³. This includes a GMP US-based R&D center, a cutting-edge R&D facility and production unit in Slovenia, Europe, and FDA-approved facilities across China. This expansion has been accompanied by a workforce exceeding 4,200 dedicated professionals, reflecting its evolution into a CDMO powerhouse with the scale and expertise to support global partners at every stage of drug development.

As of 2024, Porton has established collaborations with over 1,200 global clients, successfully delivering more than 4,000 projects and contributing to the launch of numerous innovative drugs, benefiting countless patients.



At the 20th-anniversary celebration, Oliver Ju, Chairman and CEO, delivered a heartfelt speech: “Over two decades, Porton has scaled mountains, braved storms, and navigated through darkness toward boundless horizons.” He emphasized that Porton’s achievements stem from its relentless pursuit of innovation, reverence for quality, and unwavering support from global partners. Boštjan Malovrh, Slovenian Ambassador to China, also applauded Porton’s role in strengthening China-Slovenian economic ties through innovation during the anniversary event.



As Porton Pharma Solutions celebrates its 20th anniversary and embarks on its next decade of growth, the company reaffirms its mission of “Enabling the Public’s Early Access to Good Medicines.” This milestone marks a renewed commitment to accelerating investments in R&D innovation hubs, where advanced technologies such as continuous manufacturing, structural elucidation, and particle engineering will be explored to drive breakthroughs in drug development. Simultaneously, Porton will deepen global partnerships with pharmaceutical innovators, regulators, and academia to co-create agile, patient-centric solutions, ensuring clients receive innovative and differentiated offerings that address evolving healthcare needs.

Evolving from small molecules to new drug modalities like ADC and from APIs to finished dosage forms, Porton Pharma Solutions has cemented its position as one of the leading global CDMOs, driven by an unwavering commitment to quality and customer success.

For any business cooperation opportunities, Porton’s local business development team is fully prepared to provide prompt and efficient services. Please contact us at business@portonpharma.com to explore new cooperation opportunities and jointly build a healthier future.

Porton Pharma Solutions

Porton Pharma Solutions is a global company with over 4,200 employees and R&D and GMP-compliant manufacturing facilities across the US, EU, and China. It provides customer-centric, innovative, and reliable CDMO solutions for Small Molecules, Tides, Biologics and Conjugates (such as ADCs, AOCs, PDCs, RDCs, etc.), as well as Advanced Therapy Medicinal Products, from pre-clinical to commercial stages.